Ling Yang is a Managing Director at Carlyle. She is co-head of Carlyle Asia Healthcare and is primarily responsible for Carlyle’s healthcare investment and portfolio activities in China. Ms. Yang began her career at Carlyle focusing on healthcare for the U.S. Buyout group and joined Carlyle Asia in 2011. Since joining Carlyle Asia, Ms. Yang has led investments into leading healthcare companies in China including Hutchmed, Adicon Clinical Laboratories, Ambiopharm, Microport Scientific Corporation, Meinian Onehealth, and Shenzhen Salubris Pharmaceuticals. She chairs the board of Adicon Clinical Laboratories and is a member of the boards of Ambiopharm and Shenzhen Salubris.
Prior to Carlyle Asia, Ms. Yang worked in private equity at KKR in Asia and in investment banking at Goldman Sachs in the U.S.
Ms. Yang graduated summa cum laude with a B.A. in economics and computer science from Smith College and received an M.B.A. from Harvard Business School.